The 20th Anniversary of Pegaptanib (MacugenTM), the First Approved Aptamer Medicine: History, Recent Advances and Future Prospects of Aptamers in Therapy
Pharmaceutics · 20.03.2025 · 17 (3) · 394
DOI: 10.3390/pharmaceutics17030394 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 20.03.2025. Verfasst von Miklós Bege und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, University of Debrecen, Egyetem tér 1, 4032 Debrecen, Hungary. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 300 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Debrecen Scientific Research Bridging Fund, National Research, Development and Innovation Office of Hungary.
Abstract (Originalsprache)
In addition to classic small-molecule drugs and modern protein-based biologics, an intriguing class of medicines is the therapeutic oligonucleotides. Most approved drugs in this category are antisense oligomers or those acting via RNA interference, both of which use base hybridization. Aptamers, also known as chemical antibodies form a smaller, yet equally interesting group of oligonucleotides that can recognize a wide range of molecular targets. Despite their high potential, only two aptamers have been approved to date, pegaptanib (MacugenTM) and avacincaptad pegol (IzervayTM), both for the treatment of age-related macular degeneration (AMD). Targeting vascular endothelial growth factor (VEGF), which plays an important role in the pathogenesis of many eye diseases, pegaptanib emerged as the first anti-VEGF agent and was used in various indications, further inspiring the development of other anti-VEGF therapies. In this review, we summarize the history of the first approved aptamer medicine, pegaptanib. We describe its chemistry and track its development from the earliest stages to the preclinical phase, clinical trials, and eventual regulatory approval. Additionally, we evaluate its position among other therapeutic agents and provide a comprehensive overview of pegaptanib’s efficacy, safety, and cost-effectiveness, comparing these aspects with those of monoclonal antibodies with similar indications, bevacizumab and ranibizumab.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, University of Debrecen, Egyetem tér 1, 4032 Debrecen, Hungary.
- Doctoral School of Pharmaceutical Sciences, Faculty of Pharmacy, University of Debrecen, Nagyerdei krt. 98., 4032 Debrecen, Hungary.
ORCID-Profile: Rasha Ghanem Kattoub, Anikó Borbás
Förderung
- University of Debrecen Scientific Research Bridging Fund
- National Research, Development and Innovation Office of Hungary
Zitieren
APA
Bege, M., Ghanem Kattoub, R., & Borbás, A. (2025). The 20th Anniversary of Pegaptanib (MacugenTM), the First Approved Aptamer Medicine: History, Recent Advances and Future Prospects of Aptamers in Therapy. Pharmaceutics, 17(3), 394. https://doi.org/10.3390/pharmaceutics17030394
Vancouver
Bege M, Ghanem Kattoub R, Borbás A. The 20th Anniversary of Pegaptanib (MacugenTM), the First Approved Aptamer Medicine: History, Recent Advances and Future Prospects of Aptamers in Therapy. Pharmaceutics. 2025;17(3):394. doi:10.3390/pharmaceutics17030394
BibTeX
@article{Bege2025,
author = {Bege, Miklós and Ghanem Kattoub, Rasha and Borbás, Anikó},
title = {The 20th Anniversary of Pegaptanib (MacugenTM), the First Approved Aptamer Medicine: History, Recent Advances and Future Prospects of Aptamers in Therapy},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {3},
pages = {394},
doi = {10.3390/pharmaceutics17030394}
}
EUVIMED